Medicamen Biotech Limited

Please note that the reports of Auditors are with unmodified opinion with respect to the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2022.

Please also find enclosed herewith declaration as per Regulation 33(3)(d) of SEBI (LODR), 2015 in respect of Auditor's Report with un-modified opinion for the Audited Financial Results for the quarter and year ended 31st March 2022

The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 04.00 p.m.

The Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2022, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Annexure - A

MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Audited Standalone and Consolidated Financial Results for the Quarter and Year ended on 31st March' 2022

PART I

Rupees in Lacs (Except per Share Data)

Particulars	Standalone					Consolidated				
	Quarter Ended			Year Ended		Quarter Ended			Year Ended	
	3 Months Ended 31.03.2022	3 Months Ended 31.12.2021	Corresponding 3 Months Ended 31.03.2021	31.03.2022	31.03.2021	3 Months Ended 31.03.2022	3 Months Ended 31.12.2021	Corresponding 3 Months Ended 31.03.2021	31.03.2022	31.03.2021
	Audited	Un-audited	Audited	Audited	Audited	Audited	Un-audited	Audited	Audited	Audited
Income from operations										
(a) Net Sales / Income from operations	2,275.38	3,264.09	2,033.74	11,544.52	11,014.65	2,275.38	3,264.09	2,123.86	11,544.52	11,271.01
(b) Other Income	33.76	82.75	53.72	172.01	75.40	33.76	82.75	53.72	172.01	75.40
(c) Total Revenue	2,309.14	3,346.84	2,087.46	11,716.53	11,090.06	2,309.14	3,346.84	2,177.60	11,716.53	11,347.01
Expenses										
a) Cost of Material Consumed	1,091.86	1,751.46	972.81	5,569.07	6,583.62	1,091.86	1,751.46	1,090.08	5,569.07	6,842.01
b) Purchase of Goods Traded										
c) Changes in inventory of Finished Goods and Work in Progress	(40.61)	(180.79)	(118.27)	(333.63)	384.06	(40.61)	(180.79)	(118.27)	(333.63)	484.06
d) Employees Benefits Expenses	384.30	361.72	215.53	1,450.19	879.17	384.30	361.72	233.08	1,450.19	900.17
e) Finance Cost	56.39	49.29	36.02	140.06	106.40	56.39	49.29	36.02	140.06	106.40
f) Depreciation and Amortisation Expenses	152.41	156.72	41.46	577.14	251.97	152.41	156.72	41.46	577.14	251.97
g) Other expenses	341.95	700.83	475.58	2,503.85	1,189.77	342.89	700.83	485.17	2,503.29	1,302.71
Total Expenses	1,986.30	2,839.23	1,623.12	9,906.18	9,414.94	1,987.23	2,839.23	1,767.54	9,906.27	9,887.32
Profit/(Loss) before Exceptional Items & Tax (1 - 2)	322.84	507.61	464.35	1,810.35	1,675.12	321.91	507.61	410.07	1,809.42	1,639.40
Exceptional Items (Commercial Tax Expenses Related to Earlier Years)										
Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	322.84	507.61	464.35	1,810.35	1,675.12	321.91	507.61	410.07	1,809.42	1,639.40
Tax Expenses										
Current Year	53.45	155.18	45.00	397.69	414.52	53.45	155.18	40.36	397.69	414.52
MAT Credit Entitlement										
Deferred Tax Liability	(6.08)	(25.42)	5.01	(77.98)	11.94	(6.08)	(25.42)	5.02	(77.98)	11.94
Total Tax Expense	47.37	129.76	50.01	319.71	426.46	47.37	129.76	45.38	319.71	426.46
Net Profit /Loss for the period from Continuing operation (5- 6)	275.47	377.85	414.34	1,490.64	1,248.66	274.54	377.85	364.69	1,489.71	1,212.94
Other Comprehensive Income										
Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-
Total Comprehensive Income net of Tax	275.47	377.85	414.34	1,490.64	1,248.66	274.54	377.85	364.69	1,489.71	1,212.94
Paid up equity share capital (Rs. 10/- per share)	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66
Earning Per Share (EPS)										
Basic	2.25	3.09	3.39	12.20	10.23	2.25	3.09	2.98	12.19	9.93

Medicamen Biotech Limited

R. Bhutani

MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594
E-mail : cs@medicamen.com, www.medicamen.com

STATEMENT OF ASSETS & LIABILITIES

All Figures in Rs. Lacs

	Particulars	Standalone		Consolidated	
		As at March 31,2022 Audited	As at Mar 31,2021 Audited	As at March 31,2022 Audited	As at Mar 31,2021 Audited
A	ASSETS				
1	Non-current assets				
	(a) Property, Plant and Equipment	9,211.73	8,943.49	9,211.73	8,943.49
	(b) Intangible assets	35.98	20.42	35.98	20.42
	(c) Capital work-in-progress	-	-	-	-
	(d) Financial Assets : Investments	206.14	206.14	-	-
	(e) Financial Assets : Loans and advances	86.52	77.55	86.52	77.55
	(f) Deferred Tax liabilities (Net)	49.64	(28.34)	49.64	(28.34)
	(g) Other Non- current assets	881.69	755.97	881.69	755.97
	Total Non-current Assets	**10,471.70**	**9,975.22**	**10,265.57**	**9,769.08**
2	Current assets				
	(a) Inventories	2,700.97	520.38	2,700.97	520.38
	(b) Financial Assets				
	(i) Current investments				
	(ii) Trade receivables	6,117.85	4,975.35	6,322.35	5,254.74
	(iii) Cash and Bank Balances	381.49	308.44	382.48	389.06
	(iv) Loans and advances	526.38	713.95	526.38	713.95
	(c) Other current assets	2,371.61	2,725.14	2,371.61	2,725.14
	Total current Assets	12,098.30	9,243.27	12,302.80	9,603.28
	Total Assets	**22,570.00**	**19,218.49**	**22,569.37**	**19,372.37**
B	EQUITY AND LIABILITIES				
1	Equity				
	(a) Equity share capital	1,221.66	1,221.66	1,221.66	1,221.66
	(b) Other Equity	13,582.12	12,213.65	13,425.32	12,067.29
	Total Equity	**14,803.78**	**13,435.31**	**14,646.98**	**13,288.95**
	LIBILITIES				
2	Non-current Liabilities				
	(a) Financial Libilities : Borrowings	507.36	640.46	507.36	640.46
	(b) Provisions	145.94	115.55	145.94	115.55
	(c) Deferred Tax liabilities (Net)	-	-	-	-
	Total Non-current Liabilities	**653.30**	**756.02**	**653.30**	**756.02**
3	Current Liabilities				
	(a) Financial Libilities				
	(i) Borrowings	1,927.49	1,092.87	1,927.49	1,092.87
	(ii) Trade payables	4,173.83	2,957.64	4,330.00	3,221.14
	(b) Other current liabilities	502.90	499.12	502.90	490.41
	(c) Provisions	82.32	63.03	82.32	63.03
	(d) Current tax liabilities (Net)	426.38	414.51	426.38	459.95
		7,112.92	5,027.16	7,269.08	5,327.40
	Total Equity and Libilities	22,570.00	19,218.49	22,569.37	19,372.37

For & on behalf of Board of Directors
Medicamen Biotech Limited

(Rahul Bishnoi)
Chairman

Place : New Delhi
Dated : 25.05.2022

MEDICAMEN BIOTECH LIMITED

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

CASH FLOW STATEMENT FOR THE PERIOD 01.04.2021 TO 31.03.2022

All Figures in Rs. Lacs

Particulars	STANDALONE		CONSOLIDATED	
	For the year ended 31st March, 2022	For the year ended 31st March, 2022	For the year ended 31st March, 2022	For the year ended 31st March, 2022
CASH FLOW FROM OPERATING ACTVITIES				
Net Profit/(Loss) after tax from continuing operations	1,490.64	1,248.66	1,489.71	1,212.94
Non-cash adjustment to reconcile profit before tax to net cash flows	-	-	-	-
Provision for Taxation	397.69	414.51	397.69	414.51
Adjustment for Deffered Tax	(77.98)	11.94	(77.98)	11.94
Interest expense	140.06	106.40	140.06	106.40
Loss/(profit) on sale of fixed assets	(0.12)	(0.28)	(0.12)	(0.28)
Depreciation/amortization on continuing operation	577.14	251.97	577.14	251.97
Interest income	(13.54)	(15.33)	(13.54)	(15.33)
Operating profit before working capital changes	**2,513.89**	**2,017.87**	**2,512.96**	**1,982.15**
MOVEMENTS IN WORKING CAPITAL:				
Increase/(decrease) in trade payables	1,216.19	(238.09)	1,108.86	(516.99)
Increase / (decrease) in long-term provisions	30.39	9.52	30.39	9.52
Increase / (decrease) in short-term provisions	31.44	(459.84)	(14.00)	(2.81)
Increase/(decrease) in other current liabilities	3.78	(60.33)	12.48	(100.97)
Decrease/(increase) in trade receivables	(1,142.50)	(582.34)	(1,067.61)	(365.27)
Decrease/(increase) in inventories	(2,180.59)	1,175.37	(2,180.59)	1,175.37
Decrease / (increase) in long-term loans and advances	(8.98)	(14.82)	(8.98)	(14.82)
Decrease / (increase) in short-term loans and advances	187.57	143.74	187.57	143.74
Decrease/(increase) in other current assets	353.53	275.43	353.53	(170.57)
Decrease/(Increase) in other Non-current assets	(203.71)	(522.56)	(203.71)	(522.56)
Direct taxes paid (net of refunds)	(320.00)	(446.00)	(320.00)	(446.00)
Net cash flow from/ (used in) operating activities (A)	481.01	1,297.95	410.90	1,277.14
CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of fixed assets, including intangible assets and CWIP	(860.82)	(1,796.59)	(860.82)	(1,796.59)
Purchase of non-current investments	-	-	-	-
Interest received	13.54	15.33	13.54	15.33
Net cash flow from/(used in) investing activities (B)	(847.28)	(1,781.26)	(847.28)	(1,781.26)
CASH FLOWS FROM FINANCING ACTIVITIES :				
Proceeds from issuance of share capital	-	-	-	-
Proceeds from Securities Premium	-	-	-	-
Capital Reserve	-	-	-	-
Shares Warrants	-	-	(9.52)	15.47
	-	-	-	-
Long-term borrowings net of repayment / Repayment of Long Term Borrowings	(133.10)	404.61	(133.10)	404.61
Proceeds from short-term borrowings	834.65	331.30	834.65	331.30
Interest paid	(140.06)	(106.40)	(140.06)	(106.40)
Dividends paid on equity shares	(122.17)	(61.08)	(122.17)	(61.08)
Tax on equity dividend paid	-	-	-	-
Preferational issue Expenditure	-	-	-	-
Net cash flow from/(used in) in financing activities (C)	**439.32**	**568.43**	**429.80**	**583.90**
Net increase/(decrease) in cash and cash equivalents (A + B + C)	73.05	85.12	(6.58)	79.78
Cash and cash equivalents at the beginning of the year	308.44	223.32	389.06	309.28
Cash and cash equivalents at the end of the year	**381.49**	**308.44**	**382.48**	**389.06**

For & on behalf of the Board of Directors
Medicamen Biotech Limited

Rahul Bishnoi
Chairman
(DIN: 00317960)

Place : New Delhi
Date: 25.05.2022

Annexure - B

RAI QIMAT & ASSOCIATES
CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT ON THE QUARTERLY AND YEAR TO DATE AUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 AND 52 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

TO

THE BOARD OF DIRECTORS OF
Medicamen Biotech Limited

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of Medicamen Biotech Limited (the "Company") and its subsidiary (the Company and its subsidiaries together referred to as the "Group"), for the quarter and year ended March 31, 2022 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

i. includes the results of the Wholly Owned Subsidiary i.e Opal Pharmaceuticals Pty Ltd

ii. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and

iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

404, 4th Floor, DLF Galleria Phase-IV, Gurugram-122009, Haryana
Tel. : 0124-4087353, Mob. : 9810518507
E-mail : rai.ngm@gmail.com

Emphasis of Matter:

Key audit matters are those matters that, in our professional judgement, were of most significant in our audit of the Financial Statements of the current period. These matters were addressed in the context of our audit of the financial statement as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In the audit of the current period, we do not have observed any key audit matters required to be reported separately.

Our audit opinion is not modified.

Management's Responsibilities for the Consolidated Financial Results

This Statement which includes consolidated financial results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Statement has been compiled from the audited consolidated financial statements for the three months and year ended March 31, 2022. This responsibility includes preparation and presentation of the Consolidated Financial Results that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial

assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

We communicate with those charged with governance of the Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matter

The Statement includes the financial results for the quarter ended March 31, 2022, being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2022 and published unaudited year to date figures upto the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For Rai Qimat & Associates
Chartered Accountants

CA Nimmi Devi Garg
(Partner)
Membership Number: 080857
UDIN: 22080857AJOVQX7962

Place: Gurugram
Date: 25.05.2022

INDEPENDENT AUDITOR'S REPORT ON THE QUARTERLY AND YEAR TO DATE AUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 AND 52 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

TO

THE BOARD OF DIRECTORS OF
Medicamen Biotech Limited

Report on the audit of the Standalone Financial Result

We have audited the accompanying statement of quarterly and year to date standalone financial results of Medicamen Biotech Limited (the "Company") which includes Joint Operations for the quarter and year ended March 31, 2022 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and

i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended and for the year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the quarter and year ended March 31, 2022 under the provisions of the Act and Rules

Emphasis of Matter:

Key audit matters are those matters that, in our professional judgement, were of most significant in our audit of the Financial Statements of the current period. These matters were addressed in the context of our audit of the financial statement as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In the audit of the current period, we do not have observed any key audit matters required to be reported separately.

Our audit opinion is not modified.

Management's Responsibility for the Standalone Financial Results:

This Statement, which includes the Standalone financial results is the responsibility of the Company's Board of Directors, and has been approved by them for the issuance. The Statement has been compiled from the related audited Interim condensed standalone financial statements for the three months and year ended March 31, 2022. This responsibility includes preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2022 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibility for the Audit of the Standalone Financial Results:

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matter

The Statement includes the financial results for the quarter ended March 31, 2022, being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2022 and published unaudited year to date figures upto the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For Rai Qimat & Associates
Chartered Accountants



CA Qimat Rai Garg
(Partner)
Membership Number: 080857
UDIN: 22080857AJOVXL9022

Place: Gurugram
Date: 25.05.2022

MEDICAMEN

VIVO Oncology
Quality Cancer Care

L dc h l dm Ahmsd g Khl hsdc

P E

Hhudr sn O dr dms shnm

D GHF GKHF GSR

- *CDMO agreement with a European Company*
- *Launched 12 Oncology products in Domestic Market*
- *Tech transfer for another 7 products for Domestic Market*
- *R&D developments of products in full swing which are going to be off patented in next 5 years.*
- *Our prime focus is to reach quality oncology products to cancer patients in India for which we are committed to make it available in all the leading government and private cancer care centres!*

Financial Highlights

Medicamen Biotech Limited posts yearly results with a steady revenue growth of 4.81 % YoY



TMHP TDU KTD OQN ON RHSHN MR

Differentiated Dosage Forms In Oncology

Expertise:-

- TKI's
- NDDS
- RTUs
- Extended release

Reverse Integration

- MBL develops APIs 100% of its own formulations
- Tech transfer R&D to API to formulation

Robust Product Pipeline

- Launched 12 products
- To be launched soon 7 products

Diversified product mix

- Oncology- Breast cancer, Brain Tumor, Renal Cancer, Prostate Cancer ETC.
- Cardiology
- Diabetology
- Pain Management
- CNS
- Anti Infective
- Vitamins & Minerals
- Hematology
- Lung Cancer

MEDICAMEN

VIVO Oncology
Quality Cancer Care

NMBNKNF OQNCTBSR K TMBGDC

PAZOCAM™
Pazopanib Hydrochloride Tablets 200 mg / 400 mg

Capivo™
Capecitabine Tablets IP 150 / 500 mg

Lenvamed™
Lenvatinib Capsules 4 mg / 10 mg

ABTmed™
Abiraterone Tablets 250 mg

Raxitinib™
Axitinib Tablets 1 mg / 5 mg

Dasamed™
Dasatinib Tablets 20mg / 50 mg / 70 mg / 100mg

Temo-GBM™
Temozolomide Capsules IP 20 mg / 100 mg / 250 mg

ETBmed™
Erlotinib Tablets IP 100 mg / 150 mg

Ledomed™
Lenalidomide Capsules 10 mg / 15 mg / 25 mg

AB-Taxomed™
Paclitaxel (protein bound particles) for Injectable suspension 100 mg / vial

Fasvivo
Fulvestrant Injection (250 mg/5 ml) PFS

Urea, Lactic Acid & Glycerin Cream

Radiamed™
Cream

रेडियामेड

MEDICAMEN

VIVO Oncology
Quality Cancer Care

OQNCTBSR SN AD K TMBGDC HM BTQQDMS EHM MBH K D Q

MEDIMUSTINE™
Bendamustine Injection IP 100mg/vial

PEMETOMED™
Pemetrexed for Injection 100 / 500 mg/vial

Borzomed™
Bortezomib Injection 2 mg / 3.5 mg / 3.5 mg per vial

AZACAMEN™
Azacitidine for Injection 100 mg/vial

Busmed™

AFMED™
Matinib Tablets 20 mg / 30 mg / 40 mg

Imamed™
Imatinib Tablets IP 100 mg / 400 mg

Rs sd ne s L mt e st hmf E hlshdr

y

Rs sd ne s L mt e st hmf E hlsdr

y

MEDICAMEN

VIVO Oncology
Quality Cancer Care

Qdf hr sdl dc Neeh d

e

e

MEDICAMEN Biotech Limited

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Date: 25.05.2022

To

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

BSE Code-531146

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

NSE Code: MEDICAMEQ

Subject: declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 33 (3) (d) of the Listing Regulations, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001 dated May 25,2016, Circular No CIR/CFD/CMD/56/2016 dated May 27, 2016 and Circular No CIR/CFD/CMD/56/2016 dated July 5, 2016, we hereby declare that M/s Rai Qimat & Associates, Chartered Accountants (Firm Registration No 013152C), statutory auditors of the Company have issued audit report with unmodified opinion on the audited financial results of the Company (Standalone & Consolidated) for the financial year ended on March 31,2022

This is for your information and record.

Thanking you

Yours truly
For Medicamen Biotech Limited

Medicamen Biotech Limited

Rahul Bishnoi
Director
DIN: 00317960